Latest Insider Transactions at Ani Pharmaceuticals Inc (ANIP)
This section provides a real-time view of insider transactions for Ani Pharmaceuticals Inc (ANIP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ANI PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ANI PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 22
2025
|
Thomas Haughey Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,336
+7.2%
|
-
|
|
May 22
2025
|
Patrick D Walsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,336
+5.2%
|
-
|
|
May 22
2025
|
Jeanne Thoma Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,336
+8.8%
|
-
|
|
May 22
2025
|
Renee P Tannenbaum Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,336
+13.86%
|
-
|
|
May 22
2025
|
Antonio R Pera Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,336
+10.92%
|
-
|
|
May 22
2025
|
Matthew J Leonard Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,336
+20.98%
|
-
|
|
May 15
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Open market or private sale
|
Direct |
881
-0.97%
|
$52,860
$60.07 P/Share
|
|
May 14
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Open market or private sale
|
Direct |
4,000
-3.59%
|
$240,000
$60.45 P/Share
|
|
May 13
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.5%
|
$24,800
$62.2 P/Share
|
|
May 09
2025
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
700
-0.11%
|
$53,200
$76.83 P/Share
|
|
Apr 14
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.5%
|
$27,200
$68.96 P/Share
|
|
Mar 23
2025
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,210
-3.32%
|
$397,440
$64.26 P/Share
|
|
Mar 23
2025
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,455
-3.59%
|
$1,117,120
$64.26 P/Share
|
|
Mar 19
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Open market or private sale
|
Direct |
1,866
-2.81%
|
$121,290
$65.0 P/Share
|
|
Mar 13
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.49%
|
$25,200
$63.33 P/Share
|
|
Mar 07
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
3,314
-3.52%
|
$198,840
$60.62 P/Share
|
|
Mar 07
2025
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,060
-3.39%
|
$1,023,600
$60.62 P/Share
|
|
Mar 07
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
2,874
-2.52%
|
$172,440
$60.62 P/Share
|
|
Mar 07
2025
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,150
-2.68%
|
$309,000
$60.62 P/Share
|
|
Mar 07
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-1.48%
|
$60,000
$60.86 P/Share
|
|
Mar 05
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Open market or private sale
|
Direct |
5,384
-2.71%
|
$323,040
$60.01 P/Share
|
|
Mar 05
2025
|
Ori Gutwerg SVP, GENERICS |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+0.3%
|
$9,300
$31.49 P/Share
|
|
Feb 28
2025
|
Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS |
SELL
Payment of exercise price or tax liability
|
Direct |
627
-1.36%
|
$38,247
$61.89 P/Share
|
|
Feb 28
2025
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,216
-2.37%
|
$745,176
$61.89 P/Share
|
|
Feb 28
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,275
-1.1%
|
$77,775
$61.89 P/Share
|
|
Feb 28
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,099
-1.6%
|
$67,039
$61.89 P/Share
|
|
Feb 28
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,570
-1.56%
|
$95,770
$61.89 P/Share
|
|
Feb 28
2025
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,861
-0.96%
|
$113,521
$61.89 P/Share
|
|
Feb 28
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,099
-1.34%
|
$67,039
$61.89 P/Share
|
|
Feb 21
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-1.44%
|
$60,000
$60.2 P/Share
|
|
Feb 15
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,167
-1.15%
|
$67,686
$58.92 P/Share
|
|
Feb 15
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,184
-1.02%
|
$68,672
$58.92 P/Share
|
|
Feb 14
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,426
-1.38%
|
$82,708
$58.92 P/Share
|
|
Feb 14
2025
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,799
-1.49%
|
$452,342
$58.92 P/Share
|
|
Feb 14
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,473
-1.25%
|
$85,434
$58.92 P/Share
|
|
Feb 14
2025
|
Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS |
SELL
Payment of exercise price or tax liability
|
Direct |
582
-1.25%
|
$33,756
$58.92 P/Share
|
|
Feb 14
2025
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,730
-0.88%
|
$100,340
$58.92 P/Share
|
|
Feb 14
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,434
-1.72%
|
$83,172
$58.92 P/Share
|
|
Feb 14
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,196
-1.69%
|
$69,368
$58.92 P/Share
|
|
Feb 13
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.48%
|
$23,600
$59.54 P/Share
|
|
Feb 12
2025
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
BUY
Grant, award, or other acquisition
|
Direct |
23,936
+12.06%
|
-
|
|
Feb 12
2025
|
Ori Gutwerg SVP, GENERICS |
BUY
Grant, award, or other acquisition
|
Direct |
26,112
+11.81%
|
-
|
|
Feb 12
2025
|
Nikhil Lalwani PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
152,331
+13.48%
|
-
|
|
Feb 12
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
BUY
Grant, award, or other acquisition
|
Direct |
41,346
+15.95%
|
-
|
|
Feb 12
2025
|
Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS |
BUY
Grant, award, or other acquisition
|
Direct |
13,056
+12.98%
|
-
|
|
Feb 12
2025
|
Stephen P. Carey SVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
41,346
+9.97%
|
-
|
|
Feb 12
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
28,290
+15.42%
|
-
|
|
Feb 12
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
21,761
+14.16%
|
-
|
|
Feb 12
2025
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
BUY
Grant, award, or other acquisition
|
Direct |
23,936
+14.91%
|
-
|
|
Jan 13
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.71%
|
$21,200
$53.92 P/Share
|